Publications:143
Michael J Donovan, PhD, MD
About Me
Language
English
Position
RESEARCH PROFESSOR | Pathology, Molecular and Cell Based Medicine
Publications
Selected Publications
- External validation of precisebreast, a digital prognostic test for predicting breast cancer recurrence, in an early-stage cohort from the Netherlands. Pieter J. Westenend, Claudia Meurs, Gerardo Fernandez, Marcel Prastawa, Abishek Sainath Madduri, Aaron Feliz, Juan Carlos Mejias, Alexander Shtabsky, Xiaozhu Zhang, Brandon Veremis, Rebecca DeAngel, Michael J. Donovan. Breast Cancer Research
- NF2 mutation associated with accelerated time to recurrence for older patients with atypical meningiomas. Jonathan T. Dullea, Danielle Chaluts, Vikram Vasan, John W. Rutland, Corey M. Gill, Ethan Ellis, Yayoi Kinoshita, Russell B. McBride, Joshua Bederson, Michael Donovan, Robert Sebra, Melissa Umphlett, Raj K. Shrivastava. British Journal of Neurosurgery
- Analytical validation of the LungLB test: a 4-color fluorescence in-situ hybridization assay for the evaluation of indeterminate pulmonary nodules. Michelle L. Lutman, Daniel Gramajo-Leventon, Shahram Tahvilian, Lara Baden, Courtney L. Gilbert, Michael Trejo, Eric Vail, Michael J. Donovan, Benjamin A. Katchman, Paul C. Pagano. BMC Pulmonary Medicine
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Dr. Donovan has not yet completed reporting of Industry relationships.
Mount Sinai’s faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.